These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

7238 related articles for article (PubMed ID: 2144741)

  • 1. High frequency of double drug resistance in the B16 melanoma cell line.
    McMillan TJ; Kalebic T; Stark GR; Hart IR
    Eur J Cancer; 1990; 26(5):565-7. PubMed ID: 2144741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hamster cells with increased rates of DNA amplification, a new phenotype.
    Giulotto E; Knights C; Stark GR
    Cell; 1987 Mar; 48(5):837-45. PubMed ID: 3815526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generation of drug-resistant variants in metastatic B16 mouse melanoma cell lines.
    Cillo C; Dick JE; Ling V; Hill RP
    Cancer Res; 1987 May; 47(10):2604-8. PubMed ID: 3567893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug resistance in KHT fibrosarcoma cell lines with different metastatic ability.
    Cillo C; Ling V; Hill RP
    Int J Cancer; 1989 Jan; 43(1):107-11. PubMed ID: 2910823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A possible role for topoisomerase II in cell death and N-phosphonoacetyl-L-aspartate-resistance frequency and its enhancement by 1-beta-D-arabinofuranosyl cytosine and 5-fluoro-2'-deoxyuridine.
    Goz B; Bastow KF
    Mutat Res; 1997 Aug; 384(2):89-106. PubMed ID: 9298118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of tumor promoter 12-O-tetradecanoylphorbol-13-acetate on recovery of methotrexate-, N-(phosphonacetyl)-L-aspartate-, and cadmium-resistant colony-forming mouse and hamster cells.
    Bojan F; Kinsella AR; Fox M
    Cancer Res; 1983 Nov; 43(11):5217-21. PubMed ID: 6616458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug resistance and gene amplification potential regulated by transforming growth factor beta 1 gene expression.
    Huang A; Jin H; Wright JA
    Cancer Res; 1995 Apr; 55(8):1758-62. PubMed ID: 7712485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The propensity for gene amplification: a comparison of protocols, cell lines, and selection agents.
    Sharma RC; Schimke RT
    Mutat Res; 1994 Jan; 304(2):243-60. PubMed ID: 7506368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug sensitivity and metastatic ability in B16 melanoma cells.
    Jang A; Hill RP
    Clin Exp Metastasis; 1991; 9(4):393-402. PubMed ID: 1868629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of cell growth by N-(phosphonacetyl)-L-aspartate in human and murine cells in vitro.
    Leyva A; Appel H; Smith P; Lankelma J; Pinedo HM
    Cancer Lett; 1981 Mar; 12(1-2):169-73. PubMed ID: 7273001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phenotypic resistance to methotrexate and N-phosphonacetyl L-aspartate is induced by treatment with 12-O-tetradecanoylphorbol-13-acetate (TPA).
    Kinsella AR; Fox M
    Int J Cancer; 1988 Jul; 42(1):87-93. PubMed ID: 3391708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased methotrexate resistance and dhfr gene amplification as a consequence of induced Ha-ras expression in NIH 3T3 cells.
    Wani MA; Xu X; Stambrook PJ
    Cancer Res; 1994 May; 54(9):2504-8. PubMed ID: 8162600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor activity of N-phosphonacetyl-L-aspartic acid in combination with nitrobenzylthioinosine.
    Erlichman C; Vidgen D
    Biochem Pharmacol; 1984 Oct; 33(20):3177-81. PubMed ID: 6487365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanism of resistance of variants of the Lewis lung carcinoma to N-(phosphonacetyl)-L-aspartic acid.
    Kensler TW; Mutter G; Hankerson JG; Reck LJ; Harley C; Han N; Ardalan B; Cysyk RL; Johnson RK; Jayaram HN; Cooney DA
    Cancer Res; 1981 Mar; 41(3):894-904. PubMed ID: 7459875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II evaluation of PALA and AMSA for patients with disseminated malignant melanoma.
    Creagan ET; Ahmann DL; Ingle JN; Purvis JD; Green SJ
    Cancer Treat Rep; 1981; 65(1-2):169. PubMed ID: 6894400
    [No Abstract]   [Full Text] [Related]  

  • 16. N-(phosphonacetyl)-L-aspartate (PALA) in advanced malignant melanoma: a phase II trial of the EORTC Malignant Melanoma Cooperative Group.
    Kleeberg UR; Mulder JH; Rümke P; Thomas D; Rozencweig M
    Eur J Cancer Clin Oncol; 1982 Aug; 18(8):723-6. PubMed ID: 6217975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inefficient growth arrest in response to dNTP starvation stimulates gene amplification through bridge-breakage-fusion cycles.
    Poupon MF; Smith KA; Chernova OB; Gilbert C; Stark GR
    Mol Biol Cell; 1996 Mar; 7(3):345-54. PubMed ID: 8868464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Collateral sensitivity to N-(phosphonacetyl)-L-aspartic acid in a line of P388 leukemia cells selected for resistance to L-(alpha S, 5S)-alpha-amino-3- chloro-4,5-dihydro-5-isoxazoleacetic acid (acivicin).
    Ardalan B; Jayaram HN; Johnson RK
    Cancer Res; 1983 Apr; 43(4):1598-601. PubMed ID: 6831405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved therapeutic index with sequential N-phosphonacetyl-L-aspartate plus high-dose methotrexate plus high-dose 5-fluorouracil and appropriate rescue.
    Martin DS; Stolfi RL; Sawyer RC; Spiegelman S; Young CW
    Cancer Res; 1983 Oct; 43(10):4653-61. PubMed ID: 6603903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TPA enhancement of the recovery of methotrexate and N-phosphonacetyl L-aspartate resistant mouse 3T6 cell clones is associated with transient alterations of cell cycle progression.
    Szallasi A; Fox M; Kinsella AR
    Int J Cancer; 1988 Jul; 42(1):84-6. PubMed ID: 3391707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 362.